<DOC>
	<DOCNO>NCT00672139</DOCNO>
	<brief_summary>This open-label , multicenter extension study 3200K1-4000-WW evaluate safety methylnaltrexone . This drug administer subcutaneous injection test late stage , advanced illness patient constipation cause opioid pain reliever . This study last 3 month .</brief_summary>
	<brief_title>Study Evaluating The Safety Of Subcutaneous Methylnaltrexone In Treatment Of Opioid-Induced Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>Has complete study 3200K14000WW , include 2 week therapy completion post baseline efficacy , safety , health outcome assessment . Is receive opioids regular schedule , need control pain . Likely continue need treatment OIC duration participation study . Has suspect mechanical gastrointestinal obstruction , fecal impaction , clinically important active diverticular disease determine investigator . Currently use opioid antagonist partial antagonist . Has clinically important abnormality risk patient participation outweigh potential benefit therapy determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Opioid-Induced Constipation</keyword>
</DOC>